Last reviewed · How we verify

NCT05746143

The Effect of Zolpidem on Outcomes Following Lumbar Spine Fusion

Recruiting now Phase 4 Last updated 25 June 2024
What this trial tests

Phase 4 trial testing Zolpidem Tartrate 10 mg in Spine Fusion in 140 participants. Currently enrolling.

Timeline
1 February 2022
Primary endpoint
31 January 2026
31 December 2027

Quick facts

Lead sponsorUniversity of Southern California
PhasePhase 4
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposesupportive care
Enrollment140
Start date1 February 2022
Primary completion31 January 2026
Estimated completion31 December 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Southern California

Who can join

Adults 18 to 75, any sex, with Spine Fusion or Lumbar Spine Degeneration. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate if peri-operative zolpidem for posterior lumbar spinal fusion improves patient reported outcomes following surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Spine Fusion

Currently open trials in the same condition.

Other University of Southern California trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05746143.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing